These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 32848857)

  • 21. SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Yeh YH; Kuo CT; See LC; Lip GYH
    J Clin Endocrinol Metab; 2024 Sep; 109(10):2617-2629. PubMed ID: 38466894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of sodium-glucose co-transporter-2 inhibitors on dementia and cardiovascular events in diabetic patients with atrial fibrillation.
    Chen YY; Chang HC; Lin YJ; Chien KL; Hsieh YC; Chung FP; Lin CH; Lip GYH; Chen SA
    Diabetes Metab Res Rev; 2024 Feb; 40(2):e3775. PubMed ID: 38340046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of SGLT2 inhibitors on cardiovascular events in patients with atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials.
    Zheng S; Lai Y; Jiang C; He L; Zhao Z; Li W; Tang R; Sang C; Long D; Du X; Ma C; Dong J
    Pacing Clin Electrophysiol; 2024 Jan; 47(1):58-65. PubMed ID: 38010824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of sodium glucose cotransporter 2 inhibitors on atrial tachy-arrhythmia burden in patients with cardiac implantable electronic devices.
    Younis A; Arous T; Klempfner R; Kharsa A; McNitt S; Schleede S; Polonski B; Abdallah Z; Buttar R; Bodurian C; Tabaja C; Yavin HD; Shamroz F; Wazni OM; Wittlin SD; Aktas M; Goldenberg I
    J Cardiovasc Electrophysiol; 2023 Aug; 34(8):1595-1604. PubMed ID: 37453072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of the initial decline in estimated glomerular filtration rate on the risk of new-onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes treated with sodium-glucose co-transporter-2 inhibitors.
    Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
    Diabetes Obes Metab; 2021 Sep; 23(9):2077-2089. PubMed ID: 34047459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials.
    Li D; Liu Y; Hidru TH; Yang X; Wang Y; Chen C; Li KHC; Tang Y; Wei Y; Tse G; Xia Y
    Front Endocrinol (Lausanne); 2021; 12():619586. PubMed ID: 33815278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of sodium-glucose cotransporter 2 inhibitors with risk of major adverse cardiovascular events in type 2 diabetes patients with acute coronary syndrome: a propensity score‑matched analysis.
    Liu T; Fan Z; Xiao B; He C; Wang S
    Cardiovasc Diabetol; 2024 Mar; 23(1):106. PubMed ID: 38528542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiac Structural and Electrical Remodeling: From Myocardial Cytology to Cardiodiabetology.
    Marketou M; Kontaraki J; Maragkoudakis S; Danelatos C; Papadaki S; Zervakis S; Plevritaki A; Vardas P; Parthenakis F; Kochiadakis G
    Curr Vasc Pharmacol; 2022; 20(2):178-188. PubMed ID: 34961447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of sodium-glucose cotransporter 2 inhibitors on left atrial remodeling and prognosis in patients with type 2 diabetes and heart failure with reduced ejection fraction.
    Yu S; Sun Y; Wang N; Lv X; Si J; Zhang X; Zhang Y; Liu Y
    J Cardiovasc Med (Hagerstown); 2023 Nov; 24(11):829-837. PubMed ID: 37642649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Eligibility for a Sodium-Glucose Cotransporter 2 Inhibitor and Cardiovascular Events in Patients With Atrial Fibrillation.
    Oraii A; Healey JS; Benz AP; Pandey AK; Wong JA; Fonguh S; Wang J; Conen D; Gerstein HC; Connolly SJ; McIntyre WF
    Can J Cardiol; 2022 Sep; 38(9):1434-1441. PubMed ID: 35562018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
    Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
    Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system.
    Bonora BM; Raschi E; Avogaro A; Fadini GP
    Cardiovasc Diabetol; 2021 Feb; 20(1):39. PubMed ID: 33573667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases.
    Gulsin GS; Graham-Brown MPM; Squire IB; Davies MJ; McCann GP
    Heart; 2022 Jan; 108(1):16-21. PubMed ID: 33972360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na
    Uthman L; Baartscheer A; Bleijlevens B; Schumacher CA; Fiolet JWT; Koeman A; Jancev M; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
    Diabetologia; 2018 Mar; 61(3):722-726. PubMed ID: 29197997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
    Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium-glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors.
    Lee HF; Chan YH; Chuang C; Li PR; Yeh YH; Hsiao FC; Peng JR; See LC
    Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):301-310. PubMed ID: 36639127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of > 80,000 patients (the SGLT2i-Arrhythmias and Sudden Cardiac Death).
    Liao J; Ebrahimi R; Ling Z; Meyer C; Martinek M; Sommer P; Futyma P; Di Vece D; Schratter A; Acou WJ; Zhu L; Kiuchi MG; Liu S; Yin Y; Pürerfellner H; Templin C; Chen S
    Cardiovasc Diabetol; 2024 Feb; 23(1):78. PubMed ID: 38402177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
    Zhang N; Wang Y; Tse G; Korantzopoulos P; Letsas KP; Zhang Q; Li G; Lip GYH; Liu T
    Eur J Prev Cardiol; 2022 Feb; 28(17):1961-1973. PubMed ID: 34792124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: A mini review.
    Wu J; Liu Y; Wei X; Zhang X; Ye Y; Li W; Su X
    Front Cardiovasc Med; 2022; 9():915455. PubMed ID: 36003915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice.
    Nanna MG; Kolkailah AA; Page C; Peterson ED; Navar AM
    JAMA Cardiol; 2023 Jan; 8(1):89-95. PubMed ID: 36322056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.